Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced the completion of a €47 million financing round to advance its lead program into clinical development.
Dynacure’s lead drug program, Dyn101, is an antisense oligonucleotide therapy in development for the rare and often fatal muscle disease centronuclear myopathy (CNM). Dyn101 is being developed in collaboration with Ionis Pharmaceuticals, the leading company in RNA-targeted drug discovery, development and commercialization.
Centronuclear myopathies (CNM) are a group of rare genetic muscular disorders ranging in impact from mild to severely affected, with symptoms manifesting from birth to late adulthood. Muscle weakness can affect ambulation to the point of requiring wheelchair use; respiratory muscle weakness often needs ventilatory assistance; and difficulty swallowing may require a gastric tube to ensure adequate nutrition.
The Dyn101 development program targets the Dynamin 2 protein using a cEt antisense oligonucleotide candidate developed in collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
Dynacure was founded by Kurma Partners, SATT Conectus and Ionis Pharmaceuticals in 2016, based on foundational research conducted at the Institute of Genetic and Molecular and Cellular Biology (IGBMC) in Strasbourg, France.